Donepezil Hydrochloride
Product Images NDC 42543-702

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 42543-702). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Vensun Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fig.1 (Donepezil Figure 01)

Line graph depicting changes from baseline in ADAS-cog scores over 24 weeks of drug treatment and a subsequent placebo period for Donepezil Hydrochloride at 5 mg/day and 10 mg/day doses compared to placebo. The y-axis represents mean change from baseline with clinical improvement and decline indicated, and the x-axis shows weeks of treatment and placebo phase. Error bars illustrate standard error.*

FDA Label Image

3 (Donepezil Figure 02)

A cumulative distribution plot showing the percentage of patients versus change from baseline in ADAS cognitive scores. The chart compares Donepezil Hydrochloride 5 mg/day, 10 mg/day, and placebo groups, with labeled points indicating 7-point and 4-point improvements and no change. A data inset summarizes percentage of patients achieving score changes of -7, -4, and 0 across treatment groups.*

FDA Label Image

4 (Donepezil Figure 03)

A bar chart illustrating the percentage of patients categorized by CIBIC plus Rating outcomes for placebo, 5 mg/day, and 10 mg/day groups of Donepezil Hydrochloride. The chart compares levels of improvement, no change, and worsening across treatment groups.*

FDA Label Image

5 (Donepezil Figure 04)

A line graph showing the mean change in ADAS-cog scores from baseline over 15 weeks for Donepezil Hydrochloride treatment at dosages of 5 mg/day and 10 mg/day, compared to placebo. The vertical axis indicates cognitive change, with clinical improvement above baseline and decline below. Data points include error bars representing standard error.*

FDA Label Image

6 (Donepezil Figure 05)

A cumulative percentage plot showing patient response to Donepezil Hydrochloride 5 mg/day and 10 mg/day doses compared to placebo. The x-axis represents change from baseline, and the y-axis displays cumulative percentage of patients. The graph includes labeled points at 7, 4, and 0 change in ADAS cognition score, with a table summarizing treatment group percentages at each change level.*

FDA Label Image

7 (Donepezil Figure 06)

A bar chart comparing the percentage of patients categorized by CIBIC plus Rating across three groups: placebo, 5 mg/day, and 10 mg/day. The categories range from markedly improved to markedly worse, illustrating patient response distribution to treatments.*

FDA Label Image

8 (Donepezil Figure 07)

Line graph depicting the change from baseline in SIB (Severe Impairment Battery) score over 6 months of drug treatment, comparing Donepezil Hydrochloride 10 mg/day with a placebo. The vertical axis shows SIB change from baseline (Mean ± SE), ranging from -8 to 8, while the horizontal axis represents months of treatment (0, 3, 6). Donepezil shows clinical improvement over time, whereas placebo shows clinical decline.*

FDA Label Image

9 (Donepezil Figure 08)

A cumulative percentage of patients graph comparing Donepezil Hydrochloride 10 mg/day and placebo. The x-axis shows SIB change from baseline with negative values indicating improvement; the y-axis shows cumulative percentage of patients from 0 to 100%. Two curves represent the treatment and placebo groups, showing a higher cumulative response for Donepezil Hydrochloride.*

FDA Label Image

10 (Donepezil Figure 09)

A line graph depicting the mean change from baseline in ADCS-ADL scores over 6 months of drug treatment comparing Donepezil hydrochloride 10 mg/day and placebo. The y-axis represents ADCS-ADL change from baseline, indicating clinical improvement above baseline and clinical decline below it. The graph shows Donepezil with less decline over time compared to placebo.*

FDA Label Image

11 (Donepezil Figure 10)

A cumulative percentage curve comparing Donepezil Hydrochloride 10 mg/day and placebo, depicting ADCS-ADL change from baseline on the horizontal axis and cumulative percentage of patients on the vertical axis. The graph shows two lines representing the treatment and placebo groups over a range of ADCS-ADL change values.*

FDA Label Image

10 mg (Donepezil Figure 10mg)

Donepezil Hydrochloride Tablets, USP 10 mg packaging label showing a container with 30 tablets. The label includes dosage strength, NDC number 42543-703-30, and instructions for pharmacists to dispense with a patient information leaflet. Manufactured for Vensun Pharmaceuticals, Inc. The label also advises storage conditions and child-resistant packaging.*

FDA Label Image

18 (Donepezil Figure 11)

A line chart showing the change from baseline in SIB (Severe Impairment Battery) scores over 24 weeks of drug treatment with Donepezil Hydrochloride at doses of 10 mg/day and 23 mg/day. The vertical axis measures SIB change from baseline, indicating clinical improvement and decline, while the horizontal axis shows weeks of treatment. The 23 mg/day dose shows a greater improvement compared to the 10 mg/day dose throughout the timeline.*

FDA Label Image

19 (Donepezil Figure 12)

A line graph displaying the cumulative percentage of patients plotted against SIB change from baseline for Donepezil Hydrochloride 5 mg and 10 mg doses. The graph shows patient response distribution with two overlapping curves indicating similar trends for both dose levels.*

FDA Label Image

20 (Donepezil Figure 13)

A bar chart depicting the CIBIC-plus rating distribution for patients treated with Donepezil hydrochloride at doses of 10 mg/day and 23 mg/day. The x-axis shows the CIBIC-plus rating categories from markedly improved to markedly worse, while the y-axis shows the percentage of patients in each category. The chart compares patient responses between the two dosage groups.*

FDA Label Image

5 mg (Donepezil Figure 5mg)

Donepezil Hydrochloride Tablets, USP, 5 mg, label for a 30-tablet bottle by Vensun Pharmaceuticals, Inc. The label includes dosage strength, NDC 42543-702-30, storage instructions, and dispensing information. It states to dispense with accompanying patient information and notes Rx only. Manufactured by ScieGen Pharmaceuticals, Inc.*

FDA Label Image

Str (Donepezil Figure Structure)

Chemical structure of Donepezil Hydrochloride showing the molecular arrangement including methoxy groups, a piperidine ring, and hydrochloride component.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.